Amer Zeidan, MBBS

Amer Zeidan, MBBS, discusses common adverse events and toxicity management for imetelstat in patients with myelodysplastic syndromes.

Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.

Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.

Amer Zeidan, MBBS, explains how the approval of imetelstat may impact patients with myelodysplastic syndromes.

Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.

Amer Zeidan, MBBS, discusses the unmet needs that exist for myelodysplastic syndromes and how imetelstat may help fill these needs.

Amer Zeidan, MBBS, discusses how imetelstat compares with other treatments for patients with low-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.

Amer Zeidan, MBBS, discusses imetelstat and the IMerge/MDS3001 study of the agent in patients with lower-risk myelodysplastic syndromes with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents.

In the fourth article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.

Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.

Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.

Closing remarks on the overall clinical implications of imetelstat data, and patient populations that could benefit the most from it.

Insights on patient-reported fatigue from the IMerge trial, reviewing imetelstat data and its potential to address an unmet need in lower-risk MDS.

A closer look at disease modifying treatments in MDS, providing insights into their mechanisms of action and impact on the management of the disease.

Expert oncolgists examine 1-year follow-up data from the IMerge trial, discussing the durability of response (transfusion independence), the impact of imetelstat on hemoglobin levels, key safety outcomes and managing cytopenias.

Amer Zeidan, MBBS, closes his discussion with a look at the potential implications of the COMMANDS trial data on the treatment of lower-risk MDS in clinical practice.

Dr Amer Zeidan details the design, patient population, and key efficacy and safety data from the phase 3 COMMANDS trial investigating luspatercept for the frontline treatment of lower-risk MDS with anemia.

Amer Zeidan, MBBS, explains the treatment options for patients with lower-risk MDS prior to the approval of luspatercept.

An overview of the patient population and study design of the IMerge trial evaluating imetelstat, highlighting its MOA and rationale for its use in MDS, and reviews key efficacy outcomes, including HgB levels and transfusion independence.

Dr. Zeidan discusses first-line treatment options and the role of ESAs, while Dr. Savona reviews second-line treatment options and factors influencing treatment decisions in lower-risk MDS.

Dr Savona and Dr. Zeidan define lower- vs higher-risk MDS, describe their approach to risk stratification, and share how assessing risk is critical for developing treatment plans for patients.

Michael Savona, MD and Amer Zeidan, MBBS review the biology underlying myelodysplastic syndrome and explain the patient journey from symptom presentation to official diagnosis.

Dr Amer Zeidan explains the criteria he uses to assess risk in MDS, and why it is important to initiate treatment for lower-risk patients early.

Amer Zeidan, MBBS, discusses the signs and symptoms of lower-risk MDS and the tests typically used for diagnosis.